Lieber Institute Inc

Programs: Clinical sciences: the clinical sciences division investigates mechanisms of schizophrenia and related brain disorders in clinical studies and in biological material from clinical samples specifically ascertained, evaluated, and managed by lieber institute staff and through collaborations with the national institute of mental health (nimh), peking university, university of bari (italy), sheppard pratt hospital, and others. Within the clinical sciences division, the lieber institute has programs in: genetics, epigenetics, and bioinformatics; cognitive neuroscience and imaging genetics; neuropathology; and clinical pharmacology and pharmacogenetics.

basic sciences: the creation of model systems at the lieber institute to study psychiatric illness is the major goal of the basic sciences research program. Using our unique collection of human brain material and induced pluripotent stem cell lines, we are defining the molecular signature of disease risk. To provide the basis for therapeutic intervention, we are developing new technologies using human stem cells to identify the functional consequences of genetic risk factors. Within the basic sciences division, the lieber institute has programs in: stem cell genetics; imaging development; neuroplasticity; genome informatics; developmental electrophysiology; and neurophysiology.

drug discovery: improved genetic understanding of diseases of brain development is revealing new drug discovery opportunities. Guided by genetics, the lieber institute drug discovery division is investigating new targets for psychiatric diseases, with the goal of validating innovative approaches that will lead to novel medicines for patients suffering from psychiatric disease. The drug discovery division maintains a state of the art medicinal chemistry laboratory and unique capabilities in target validation.